Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2654

Sigma-Aldrich

Telaprevir

≥90% (HPLC)

Synonym(s):

2-(2-(2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-(1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, LY-570310, VX-950

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C36H53N7O6
Molecular Weight:
679.85
MDL number:
MFCD11616089
UNSPSC Code:
12352107
NACRES:
NA.77

Assay

≥90% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

[H][C@@]1([C@@]2(CCC1)[H])CN(C([C@@H](NC([C@@H](NC(C3=NC=CN=C3)=O)C4CCCCC4)=O)C(C)(C)C)=O)[C@@H]2C(N[C@H](C(C(NC5CC5)=O)=O)CCC)=O

Biochem/physiol Actions

Telaprevir is a potent, selective and orally active hepatitis C virus (HCV) NS3.4A serine protease inhibitor. Telaprevir also inhibits chymotrypsin, chymase, elastase, and cathepsins F, K, L, S, and V in vitro

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361fd

Hazard Classifications

Repr. 2

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Robert B Perni et al.
Antimicrobial agents and chemotherapy, 50(3), 899-909 (2006-02-24)
VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC50] = 354 nM) and in human fetal
Gema Méndez-Lagares et al.
Journal of immunology (Baltimore, Md. : 1950), 200(3), 1124-1132 (2017-12-22)
The contribution of the host immune system to the efficacy of new anti-hepatitis C virus (HCV) drugs is unclear. We undertook a longitudinal prospective study of 33 individuals with chronic HCV treated with combination pegylated IFN-α, ribavirin, and telaprevir/boceprevir. We
Hiromitsu Kumada et al.
Hepatology research : the official journal of the Japan Society of Hepatology, 48(2), 184-192 (2017-05-13)
To assess the efficacy and safety of telaprevir (TVR) when used in combination with natural human interferon-β (IFN-β) and ribavirin (RBV) for genotype 1 patients with depression compared to IFN-β/RBV therapy in Japan. We also examined the efficacy of the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service